Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses.

ABSTRACT: Historically, patients diagnosed with metastatic pancreatic cancer have faced a grim prognosis. The survival benefit seen with systemic chemotherapies and even combinations thereof have been disappointing. However, growing data suggest that the microenvironment of pancreatic cancer may be contributing to this poor prognosis. This microenvironment has a dense fibrotic stroma, and is hypoxic and highly immunosuppressive, all of which pose barriers to treatment. Newer strategies looking to disrupt the fibrotic stroma, target hypoxic areas, and improve local immune responses in the tumor microenvironment are currently undergoing clinical evaluation and seem to offer great promise. In addition to these therapies, preclinical work evaluating novel cytotoxic agents including nanoparticles has als

SUBMITTER: Strauss J 

PROVIDER: S-EPMC6363002 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature